Benefits of a Cosmetic Anti-hair Loss in Males With Hair Loss

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18-41
SponsorCosmetique Active International

About this trial

Androgenetic alopecia (AGA), also known as androgenic alopecia or male pattern baldness, is the most common type of progressive hair loss. AGA is a polygenetic condition with varying severity, age of onset, and scalp location of hair loss. In men, hair loss typically involves the temporal and vertex region while sparing the occipital region: the characteristic "horseshoe" pattern. Incidence and prevalence of AGA depend on age and race.

Vichy has developed a new cosmetic anti hair loss lotion with the aim of acting on androgenic alopecia. The aim is to improve the efficacy on hair loss of the association of the lotion with finasteride versus finasteride alone.

The primary objective of this investigator-blinded, randomized multi-center study is to quantitatively evaluate, using the phototrichogram method, the efficacy of a lotion associated with finasteride versus finasteride alone on hair growth parameters in male subjects with androgenetic alopecia.

Eligibility criteria

Qualifiers

Male subject aged 18-41 years old with skin type I to IV according to the Fitzpatrick scale;

Affected by androgenetic alopecia with hair loss evaluated grade IIA to IV the modified Norwood-Hamilton scale;

Subject with chestnut brown, dark or black hair;

Subject with hair length ≥ 3 cm on the vertex and agreeing to keep this minimum length for the duration of the study;

Disqualifiers

Female subject;

Subject presenting a life-threatening endocrine disease, neoplasia or other serious diseases;

Subjects suffering from chemo-induced alopecia (poisoning, medicines), or resulting from a chronic disease (genetic, endocrine, immunological, deficiencies), seasonal hair loss;

Subject having any other concomitant dermatological affection of the scalp (psoriasis, seborrheic dermatitis, eczema, other alopecia than androgenetic);

Trial design

Treatments tested in this trial

  • Aminexil® active+ lotion
  • Finasteride 1mg

Treatment groups

140 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Cosmetique Active International

Lead sponsor

Centre Hospitalier Universitaire de Nice

Collaborator

Saint-Louis Hospital, Paris, France

Collaborator